Core Viewpoint - Changfeng Pharmaceutical (02652) has submitted a filing application to the China Securities Regulatory Commission (CSRC) for the proposed implementation of full circulation of H-shares, converting approximately 107.4 million unlisted domestic shares into H-shares on a one-to-one basis [1] Group 1 - The company plans to convert approximately 107.4 million unlisted shares into H-shares, which will then be listed and traded on the Hong Kong Stock Exchange [1] - The conversion is subject to the completion of all filing requirements, including approval from the CSRC and the Hong Kong Stock Exchange [1] - Upon completion, the 107.4 million unlisted shares will become 107.4 million H-shares, facilitating their trading on the exchange [1]
长风药业(02652)就建议实施H股全流通向中国证监会备案